News | November 28, 2025
Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Subscribe To Our Newsletter & Stay Updated
